Session Recap: Viewing Unusual Volume for Revance Therapeutics, Inc. (NASDAQ:RVNC)

Lloyd Doyle
December 7, 2017

A sudden increase in activity can be a sign that investors are trading in anticipation of a catalyst. Its up 0.99, from 0.97 in 2017Q1. Looking at the stock's movement on the chart, Revance Therapeutics, Inc. recorded a 52-week high of $37.20. Parametric Associate Limited Liability Company stated it has 0% in Revance Therapeutics, Inc. Revance Therapeutics, Inc. (NASDAQ:RVNC) has risen 20.40% since December 7, 2016 and is uptrending. (NASDAQ:RVNC) to report earnings on February, 26. State Of Wisconsin Inv Board holds 0% or 18,000 shares. Royal National Bank Of Canada has 0% invested in Revance Therapeutics, Inc. 54,166 are owned by Rothschild Asset Mgmt. Essex Woodlands Ventures Incorporated holds 21.92% or 4.59M shares in its portfolio.

Several large investors have recently bought and sold shares of the company. New York-based Blackrock has invested 0% in Revance Therapeutics, Inc. Polar Capital Limited Liability Partnership invested in 0.46% or 1.30 million shares. Following the completion of the sale, the chief executive officer now owns 148,450 shares of the company's stock, valued at approximately $3,500,451. Metropolitan Life Insur reported 0% stake. However, the company's most recent quarter decrease of 0% looks unattractive. Connecticut-based Trexquant Investment L P has invested 0.06% in Revance Therapeutics, Inc. For the current quarter Revance Therapeutics (NASDAQ:RVNC) has high EPS estimates of $-0.89 in contradiction of low EPS estimates of $-1.02.

Separately, Zacks Investment Research upgraded shares of Revance Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday, March 1st. Therefore 90% are positive. Revance Therapeutics has a twelve month low of $15.85 and a twelve month high of $37.20.

Taking a peek at some Moving Averages, the 200-day is at 23.53, the 50-day is 26.60, and the 7-day is sitting at 27.81. Revance Therapeutics had 19 analyst reports since August 22, 2015 according to SRatingsIntel. FMR LLC acquired a new stake in Revance Therapeutics during the fourth quarter valued at about $2,070,000. Piper Jaffray maintained the stock with "Buy" rating in Tuesday, July 25 report. The rating was initiated by Guggenheim with "Buy" on Tuesday, December 5. Aegis Capital maintained it with "Buy" rating and $3600 target in Thursday, June 8 report. Suntrust Robinson maintained Revance Therapeutics, Inc.

RVNC's revenue has declined at an average annualized rate of about -11.6% during the past five years. Revance Therapeutics has an average rating of "Buy" and a consensus target price of $40.75.

pdvWireless, Inc. (PDVW) stock is interesting player of Wall Street Market in Wednesday trading. (NASDAQ:RVNC) has "Buy" rating given on Thursday, July 20 by Cantor Fitzgerald.

TRADEMARK VIOLATION NOTICE: "Revance Therapeutics (RVNC) Now Covered by Guggenheim" was published by The Lincolnian Online and is the property of of The Lincolnian Online. The ROIC 5 year average of Revance Therapeutics, Inc. The firm earned "Buy" rating on Thursday, November 16 by Mizuho.

Swiss Bancorporation stated it has 0% of its portfolio in Revance Therapeutics, Inc. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. Natl Bank Of Mellon owns 2.08 million shares. Revance Therapeutics (RVNC) now has a 14 day Williams %R of -27.95. It has outperformed by 3.70% the S&P500. Finally, Alps Advisors Inc. increased its position in Revance Therapeutics by 11.1% during the third quarter. That suggests something of the likelihood of a short squeeze in shares of RVNC. Insider ownership during the a year ago has increased by a net of 82116 shares. The relative volume of the stock is 42.14 while its market cap is $1.05 billion. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value. Finally, Candriam Luxembourg S.C.A. increased its position in shares of Revance Therapeutics by 14.8% during the 2nd quarter. (NASDAQ:RVNC). 179,657 are held by Goldman Sachs Grp Incorporated.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article